Florida International University

FIU Digital Commons
Biomolecular Sciences Institute: Faculty
Publications

College of Arts, Sciences & Education

3-1-2021

Exonuclease VII repairs quinolone-induced damage by resolving
DNA gyrase cleavage complexes
Shar-Yin N. Huang
Laboratory of Molecular Pharmacology, Developmental Therapeutics Branch, Center for Cancer Research,
National Cancer Institute

Stephanie A. Michaels
Laboratory of Molecular Pharmacology, Developmental Therapeutics Branch, Center for Cancer Research,
National Cancer Institute

Brianna B. Mitchell
Laboratory of Molecular Pharmacology, Developmental Therapeutics Branch, Center for Cancer Research,
National Cancer Institute

Nadim Majdalani
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda,
MD 20892, USA.

Arnaud Vanden Broeck
Integrated Structural Biology Department, IGBMC, UMR7104 CNRS, U1258 Inserm, University of
Strasbourg
Follow
this
andfor
additional
works
at: https://digitalcommons.fiu.edu/biomolecular_fac
See next
page
additional
authors

Recommended Citation
Huang SN, Michaels SA, Mitchell BB, Majdalani N, Vanden Broeck A, Canela A, Tse-Dinh YC, Lamour V,
Pommier Y. Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage
complexes. Sci Adv. 2021 Mar 3;7(10):eabe0384. doi: 10.1126/sciadv.abe0384. PMID: 33658195; PMCID:
PMC7929499.

This work is brought to you for free and open access by the College of Arts, Sciences & Education at FIU Digital
Commons. It has been accepted for inclusion in Biomolecular Sciences Institute: Faculty Publications by an
authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

Authors
Shar-Yin N. Huang, Stephanie A. Michaels, Brianna B. Mitchell, Nadim Majdalani, Arnaud Vanden Broeck,
Andres Canela, Yuk-Ching Tse-Dinh, Valerie Lamour, and Yves Pommier

This article is available at FIU Digital Commons: https://digitalcommons.fiu.edu/biomolecular_fac/36

SCIENCE ADVANCES | RESEARCH ARTICLE
BIOCHEMISTRY

Exonuclease VII repairs quinolone-induced damage by
resolving DNA gyrase cleavage complexes
Shar-yin N. Huang1*, Stephanie A. Michaels1, Brianna B. Mitchell1, Nadim Majdalani2,
Arnaud Vanden Broeck3, Andres Canela4, Yuk-Ching Tse-Dinh5, Valerie Lamour3, Yves Pommier1*
The widely used quinolone antibiotics act by trapping prokaryotic type IIA topoisomerases, resulting in irreversible topoisomerase cleavage complexes (TOPcc). Whereas the excision repair pathways of TOPcc in eukaryotes
have been extensively studied, it is not known whether equivalent repair pathways for prokaryotic TOPcc exist. By
combining genetic, biochemical, and molecular biology approaches, we demonstrate that exonuclease VII (ExoVII)
excises quinolone-induced trapped DNA gyrase, an essential prokaryotic type IIA topoisomerase. We show that
ExoVII repairs trapped type IIA TOPcc and that ExoVII displays tyrosyl nuclease activity for the tyrosyl-DNA linkage
on the 5′-DNA overhangs corresponding to trapped type IIA TOPcc. ExoVII-deficient bacteria fail to remove
trapped DNA gyrase, consistent with their hypersensitivity to quinolones. We also identify an ExoVII inhibitor that
synergizes with the antimicrobial activity of quinolones, including in quinolone-resistant bacterial strains, further
demonstrating the functional importance of ExoVII for the repair of type IIA TOPcc.

INTRODUCTION

Topoisomerases are the target of widely used anticancer drugs and
antibiotics (1–5). Quinolone antibiotics, in particular, ciprofloxacin,
are on the World Health Organization’s List of Essential Medicines
(6, 7). Collectively termed as topoisomerase poisons, these drugs
bind to a transient pocket at the covalent enzyme-DNA interface
during the catalytic cycles of topoisomerases as they cleave DNA
backbone(s) to adjust DNA topology (1, 3, 8, 9). Trapping of
topoisomerase-DNA cleavage complexes (TOPcc) is the initiating
event in the killing of bacteria and cancer cells by antibacterial and
anticancer topoisomerase poisons, respectively. Previous studies
revealed that the repair of TOPcc in eukaryotes relies on their excision by the tyrosyl-DNA phosphodiesterase (TDP1 and TDP2)
enzymes, which hydrolyze the covalent bond between the trapped
topoisomerase catalytic tyrosine and the DNA end (10). Thus,
eukaryotic TDP enzymes have become rational drug targets as their
inactivation synergizes with anticancer topoisomerase poisons (10).
Yet, despite the wide usage of quinolones, the repair pathways of
prokaryotic TOPcc are much less understood than the repair of
TOPcc in eukaryotes, and until now, no TDP activity has been identified in prokaryotes.
Escherichia coli strains deficient in DNA double-strand break
repair or the RuvABC resolvasome machinery (involved in Holliday
junction resolution) are hypersensitive to ciprofloxacin, as these
pathways are likely required for rejoining the DNA ends after the
excision of the TOPcc (11, 12). Intriguingly, loss of exonuclease VII
(ExoVII), a nuclease capable of degrading single-stranded DNA
in vitro but without well-defined biological functions (13), has been
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associated with hypersensitivity to quinolones (11, 12, 14–16). This
observation led us to examine whether ExoVII, a multimeric complex composed of a catalytic subunit, XseA (encoded by xseA), and
multiple regulatory subunits, XseB (encoded by xseB), could act as
a repair nuclease for trapped TOPcc in bacteria. In the current
study, we combine genetic, biochemical, and molecular biology
approaches to demonstrate that ExoVII repairs quinolone-induced
DNA damage by excising trapped DNA gyrase. We also identify an
ExoVII inhibitor that synergizes with the antimicrobial activity of
ciprofloxacin and could potentially increase the efficacy of quinolones, particularly in the strains that have developed quinolone
resistance.
RESULTS

ExoVII-deficient E. coli strains are hypersensitive to trapped
type IIA topoisomerase
To understand the role of ExoVII in the repair of quinolone-
induced DNA damage, we first confirmed that inactivation of
ExoVII in E. coli leads to hypersensitivity to ciprofloxacin, which
traps type IIA TOPcc (8). Compared to wild-type (WT) strains, deficiency in either subunit of ExoVII (xseA or xseB) decreased the
minimum inhibitory concentration (MIC) of ciprofloxacin by 60 to
70% (Fig. 1A and fig. S1, A and B). ExoVII-deficient strains are not
hypersensitive to the non–quinolone topoisomerase catalytic inhibitor novobiocin (15), suggesting that ExoVII is specifically involved
in repairing trapped DNA gyrase rather than damages stemming
from the loss of DNA gyrase activity.
Bacterial strains in the clinical settings frequently develop quinolone resistance by acquiring mutations in the quinolone resistance–
determining region that lead to reduced binding of quinolones to
the type IIA topoisomerases (17–19). To determine whether inactivating ExoVII in quinolone-resistant strains can resensitize bacteria
to quinolones, we genetically modified DNA gyrase, the primary target of quinolones among the two type IIA topoisomerases in E. coli.
We introduced a leading recurrent mutation to the DNA gyrase
GyrA subunit, gyrA-S83L (20), that leads to quinolone resistance.
Because DNA gyrase is essential in E. coli, we first transformed the
1 of 10
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Fig. 1. Loss of ExoVII sensitizes E. coli strains with both the WT and quinolone-
resistant backgrounds to ciprofloxacin, which traps type IIA topoisomerases.
By contrast, loss of ExoVII does not sensitize E. coli to trapped type IA topoisomerase (A). Average MIC values for ciprofloxacin (Cipro) in WT strain or strains deficient
in either subunit of ExoVII (xseA and xseB) (n ≥ 4). Statistical significance was calculated using two-tailed Student’s t test in GraphPad Prism. **P < 0.01. ***P < 0.001.
(B) Same as in (A), except that the E. coli strains express the quinolone-resistant
mutation in the catalytic subunit of DNA gyrase, GyrA-S83L. (C) Transformants with
pY. pestis topA (pYtopA, encoding YTop1) or pY. pestis topA-R327W (pYtopA-R327W,
encoding YTop1-R327W) were established in either the WT, xseA, or xseB strains.
Left panel shows the spotted growth of serial dilutions of pYtopA transformants
after induction with 0.2% arabinose for 2 hours. Middle and right panels show the
growth of the uninduced or induced pYtopA-R327W transformants, respectively.
The dilution of each sample is indicated above the images. Columns of equal spotting densities are indicated by red circles. Representative plates of duplicates are
shown. (D) Growth of pYtopA-R327W transformants under continuous induction
with the indicated concentrations of arabinose. Representative plates of duplicates are shown.

strains proficient or deficient in ExoVII (wild-type, xseA, or xseB)
with a single-copy plasmid carrying gyrA-S83L (pgyrA-S83L) (17–19),
followed by inactivation of the genomic copy of gyrA (fig. S1C). As
expected, the mutation gyrA-S83L led to resistance to ciprofloxacin,
reflected by a 10-fold increase in ciprofloxacin MIC (compare Fig. 1, A
and B). Inactivating either subunit of ExoVII in the gyrA-S83L strain
resensitized the bacteria to quinolones by ~2-fold (Fig. 1B and fig. S1D)
(12, 21), demonstrating the functional importance of ExoVII in the
quinolone-resistant bacteria strains.
The other major topoisomerases in prokaryotes are type IA topoisomerases, which also form transient covalent bond to the 5′-end
of DNA but change DNA topology by generating DNA single-strand
breaks rather than concerted DNA double-strand breaks (8, 22, 23).
To examine whether ExoVII also plays a role in repairing type IA
TOPcc, we induced expression of a mutated type IA topoisomerase,
Yersinia pestis topoisomerase I-R327W (YTop1-R327W), that leads
to accumulation of toxic covalently linked Top1 (22, 24). We used
Y. pestis Top1 (encoded by YtopA) because it shares ~85% sequence
Huang et al., Sci. Adv. 2021; 7 : eabe0384
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identity with E. coli Top1, yet the clone with the dominant lethal
mutant YtopA is more stable (22). In both ExoVII-proficient and
ExoVII-deficient strains (WT, xseA, and xseB), induction of the
control empty vector or WT YTop1 by arabinose showed comparable growth to the uninduced YTop1-R327W cells (Fig. 1C and fig.
S2). By contrast, induction of YTop1-R327W decreased survival by
more than 1000-fold (Fig. 1C and fig. S2), confirming the detrimental
effects of YTop1-R327W. Notably, we did not observe any additional growth defects in the ExoVII-deficient strains. We also did
not observe any difference in growth rates between the WT and
ExoVII-deficient strains when YTop1-R327W was continuously induced by arabinose (Fig. 1D). These results suggest that ExoVII is
involved in the repair of trapped type IIA but not type IA topoisomerases in bacteria.
ExoVII removes 5′-tyrosyl adducts mimicking trapped type
IIA topoisomerase
To examine whether ExoVII shares biochemical attributes similar
to eukaryotic TDP enzymes for excision of tyrosyl-DNA linkages,
we conducted biochemical assays with recombinant ExoVII. We
first tested whether ExoVII could excise tyrosine adducts on the
5′-end of DNA, which is a mimetic of trapped type IIA TOPcc.
DNA substrates were internally radiolabeled and contained phosphorothioate linkages at their 3′-ends to track only the potential excision activity of ExoVII for DNA 5′-ends. ExoVII was capable of
removing the tyrosine adduct from a 4-nucleotide (nt) overhang
at the 5′-end of DNA (Y-40) (Fig. 2A). We refer to this activity of
ExoVII as the tyrosyl nuclease activity since it was specific for the
tyrosine adducts on the 5′-end, and ExoVII did not cleave constructs
bearing 5′-phosphate or 5′-hydroxyl groups (Fig. 2A). Alkaline
phosphatase (CIP) treatment of the ExoVII cleavage product resulted
in an upper shift (Fig. 2B), corresponding to the conversion of the
terminal 5′-phosphate group into a 5′-hydroxyl group. Therefore,
our biochemical analysis shows that the tyrosyl nuclease activity
of ExoVII converted the Y-40 substrate into a 39-nt product with a
5′-phosphate group (Fig. 2B). The structures of the DNA constructs
and ExoVII-specific cut site are shown in Fig. 2C.
After demonstrating that ExoVII could excise tyrosine adducts
on 5′-DNA ends, we compared the tyrosyl nuclease activity of ExoVII
for a series of DNA substrates with tyrosine adducts on varying
length of 5′-overhangs (Fig. 2D). The tyrosyl nuclease activity of ExoVII
was detected only with an overhang of 4 nt or more, as ExoVII was
inactive for substrates with 2-nt overhangs or blunt ends (Fig. 2D).
Incidentally, trapped type IIA topoisomerase in the cells is expected
to be linked to the 5′-end of DNA with a 4-nt overhang (8, 25). We
also found that the tyrosyl nuclease activity of ExoVII generated the
same major products from substrates with either 4- or 6-nt overhangs (39-nt product with 5′-phosphate; Fig. 2D). In addition,
ExoVII generated a shorter minor product in the case of 6-nt overhangs, suggesting that longer overhangs potentially confer higher
processivity of ExoVII, consistent with its previously established
exonuclease activity for single-stranded substrate (26). We verified
that ExoVII enzyme from another independent source showed the
same in vitro biochemical properties revealed here (fig. S3A).
To compare ExoVII’s tyrosyl nuclease activity with its single-
stranded exonuclease activity, we tested the activity of ExoVII for
5′-tyrosine on a 4-nt overhang versus a substrate with 5-nt overhang (fig. S3B), where the single-stranded regions of the two substrates are comparable in length. ExoVII processed both substrates
2 of 10

SCIENCE ADVANCES | RESEARCH ARTICLE
A

C

Y-40

X

COOH

3’

32P

X=

OH

O
O
NH
OO P
N O
O
O

H2N
O

36 nt
P

H2 N

COOH

Y

Cut
site

Singlestranded
overhang

ExoVII

O
NH
OO P
N O
O
O
NH2
O
N
OO P
N O
O
O
NH2
O
N
OO P
N O
O
O

OH

ExoVII

Y-40
ExoVII
product

O
N
OO P
N
O
O

O
NH
N

NH2
OH
N
OO P
N O
O
O
NH2
O
N
OO P
N O
O
O

NH2

O
N
OO P
N
O
O

O

O
NH
N

NH2

O

5’-P

ExoVII
CIP

5’-O

H-3
9m
ar
-39
ma ker
rke
r

B

+ +
+

D

Cut site

Y

Y-40

3’

32P

n: nt overhang
n =

0

2

4

6

ExoVII

Y-40
5’-OH-39
5’-P-39

Fig. 2. Recombinant ExoVII shows selective tyrosyl nuclease activity for tyrosyl-DNA linkages on 5′-overhangs. (A) The upper strands of all three DNA constructs
were internally radiolabeled. The constructs differ only by the terminal chemical group of the 5′-overhangs, phosphate (X = P), hydroxyl (X = OH), or phosphotyrosine
(X = Y). Concentrations of ExoVII ranged from 0.033 to 0.1 U/l. The DNA cleavage products were resolved on a 20% denaturing polyacrylamide gel electrophoresis (PAGE).
A representative gel of three independent experiments is shown. (B) The tyrosyl nuclease activity of ExoVII processes the Y-40 construct [same as in (A)] to generate a
39-nt product bearing a 5′-phosphate. Treatment of ExoVII-generated product with alkaline phosphatase (CIP) removes the 5′-phosphate, as demonstrated by the two
39-nt markers bearing either a 5′-phosphate or 5′-hydroxyl group. Note that the oligo bearing an additional phosphate group travels faster in PAGE. (C) Scheme of the
specific cleavage activity of ExoVII for 5′-tyrosine adducts. The single-stranded overhang regions and the site of ExoVII cleavage are indicated (red arrow). (D) The length
of the 5′-overhangs influences the tyrosyl nuclease activity of ExoVII. Constructs differed only in the complementary lower strands, resulting in 5′-overhangs with different
lengths. Concentrations of ExoVII ranged from 0.033 to 0.1 U/l. A representative gel of five independent experiments is shown.

similarly, with a slightly higher efficiency for the tyrosine adducts
(fig. S3, B and C). We also compared DNA constructs with varying
lengths in their duplex regions. The tyrosyl nuclease efficiency of
ExoVII increased with DNA constructs containing longer duplex
regions (fig. S4, A and B). The fact that longer duplex regions lead
to higher cleavage efficiencies of ExoVII suggests a mechanism
where ExoVII likely could bind and scan the duplex DNA before
locating its single-stranded cleavage substrates at the end.
The other major class of topoisomerase, type IB topoisomerases,
is largely absent from the bacterial domain with the exception of a
handful of species (27, 28). While type IA and type IIA topoisomerases form cleavage complexes on the 5′-end of DNA, type IB topoisomerase forms cleavage complex on the 3′-end of DNA. To
further define the substrate specificity of ExoVII, we tested the
tyrosyl nuclease activity of ExoVII for tyrosine adducts on 3′-DNA
overhangs. As expected, because of its exonuclease activity, ExoVII
degraded DNA substrates with 3′-overhangs but not the substrates
with blunt ends. Furthermore, ExoVII degraded substrates with tyrosine adducts on 3′-overhangs to the same degree as the substrates
bearing a phosphate or a hydroxyl group on the 3′-overhangs (fig.
S5A). We conclude that the presence of a tyrosine adduct on the
Huang et al., Sci. Adv. 2021; 7 : eabe0384
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3′-overhangs has no impact on the 3′-single-stranded exonuclease
activity of ExoVII.
To complete our biochemical analyses, we tested ExoVII activity
for tyrosine adducts on 5′-overhangs of RNA because type IA topoisomerases have been shown to act as RNA topoisomerases (29, 30).
We could not detect any ExoVII tyrosyl nuclease activity for tyrosine-
RNA linkages (fig. S5B). In addition, because ExoVII is known to
cleave single-stranded DNA and type IIA topoisomerase can generate
single-strand breaks (8), we compared the ExoVII exonuclease efficiency for single-stranded DNA with or without the 5′-tyrosine
adducts. The exonuclease activity of ExoVII was similar for both substrates (fig. S5C). Together, these results demonstrate the specificity of
ExoVII tyrosyl nuclease activity for substrates derived from type IIA
TOPcc. Consistent with the tyrosyl nuclease activity of ExoVII reported
here, a recent study used ExoVII to construct libraries for the purpose
of genome-wide mapping of trapped TOP2 sites by END-seq (31).
ExoVII-deficient E. coli strains accumulate more
ciprofloxacin-induced trapped DNA gyrase
To establish the tyrosyl nuclease activity of ExoVII in bacteria, we reasoned that inactivating ExoVII would lead to increased accumulation
3 of 10
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Denaturation of trapped DNA gyrase is required for
ExoVII-mediated excision
The eukaryotic TDP enzymes cannot efficiently excise TOPcc
unless the TOPcc is first unfolded or digested (10, 36–41). Hence,
we examined whether the tyrosyl nuclease activity of ExoVII is
capable of excising native trapped DNA gyrase generated with recombinant DNA gyrase and radiolabeled DNA substrates. In the
presence of ciprofloxacin, the majority of DNA substrate (30 nt long)
became retained in the wells of sequencing gels as a result of covalent attachment to the DNA gyrase (fig. S9). The addition of ExoVII
failed to resolve the DNA gyrase TOPcc and to release the DNA from
the wells (fig. S9), indicating that ExoVII is unable to process native
intact DNA gyrase cleavage complexes.
To test whether ExoVII could process denatured DNA gyrase
TOPcc, we isolated the DNA gyrase TOPcc with the RADAR assays, where the polypeptide chains of the DNA gyrase TOPcc are
denatured by guanidinium isothiocyanate. Similar to the prior
biochemical experiments, the DNA gyrase TOPcc cannot enter
the polyacrylamide gels unless the covalently linked DNA is first
digested away. Upon complete digestion of the genomic DNA,
the released DNA gyrase can subsequently enter the polyacrylamide gels and become detectable by immunoblots (untreated
versus benzonase-treated samples, Fig. 3C). Treating the denatured
DNA gyrase TOPcc with ExoVII also led to the release of full-
length DNA gyrase (detected in immunoblot in Fig. 3C), demonstrating that ExoVII can excise covalently-linked DNA gyrase
from DNA when the peptide is denatured, similar to eukaryotic
TDP enzymes.
Huang et al., Sci. Adv. 2021; 7 : eabe0384

3 March 2021

A

WTxseAxseBCipro pgyrAHis pgyrAHis pgyrAHis

WTxseAxseBpgyrAHis pgyrAHis pgyrAHis

+

3

C

**

*

260 kDa
2

160 kDa
125 kDa

1

GyrAHis
Hi

s
Hi

90 kDa
70 kDa

xs

eB

-p
gy

rA

rA

Hi

-p
gy

rA

eA
xs

Tpg
y

s

0
s

Normalized GyrAHis (A.U.)

B

Anti-DNA

Un
tre
Be ated
nz
o
Ex nas
oV e
II

Anti-His-tag (GyrA)

W

of trapped DNA gyrase on genomic DNA. To facilitate the detection of trapped DNA gyrase in vivo, we introduced a C-terminal
His-tagged GyrA on a single-copy plasmid (pgyrAHis) into WT,
xseA, and xseB E. coli strains. As expected, only transformants of
pgyrAHis showed detectable GyrAHis expression (fig. S6A). Immunoblots probed with anti-GyrA antibodies confirmed that the exogenous GyrAHis was expressed at levels close to that of endogenous
GyrA to minimize any potential perturbations caused by exogenous
expression of GyrA (fig. S6B). All transformants displayed similar
levels of sensitivity to quinolones and comparable MIC for ciprofloxacin as the nontransformed strains (figs. S6, C and D, S1, A and
B; and Fig. 1A).
Using these transformant strains in a modified rapid approach
to DNA adduct recovery (RADAR) assay (fig. S7A) (32–34), we
detected trapped DNA gyrase on genomic DNA in vivo upon ciprofloxacin treatment in a dose-dependent manner (fig. S7B). Having
optimized the RADAR assay, we measured trapped DNA gyrase levels
in different transformant strains after a 6-hour treatment with clinical
plasma concentration of ciprofloxacin (~0.5 g/ml) (35). ExoVII-deficient
transformant strains (xseA-pgyrAHis and xseB-pgyrAHis) accumulated significantly more trapped DNA gyrase than the WT
transformant strain (WT-pgyrAHis) (Fig. 3, A and B). The levels of
DNA in each sample probed with anti-DNA antibody served as
loading controls. The enhanced accumulation of trapped DNA gyrase
correlated with the decreased survival rates of the ExoVII-deficient
transformant strains (fig. S8A). The ExoVII-deficient strains also
showed hypersensitivity to ciprofloxacin even with relatively short
treatments (fig. S8B). Combined, these results support the conclusion that ExoVII is directly involved in the repair of trapped DNA
gyrase in vivo.

Fig. 3. ExoVII-deficient E. coli strains accumulate trapped DNA gyrase upon
ciprofloxacin treatment. (A) E. coli WT and strains deficient in either subunit of
ExoVII, xseA or xseB were transformed with a single-copy plasmid bearing gyrA
with a C-terminal His-tag (pgyrAHis). Each transformant strain was grown to log phase
and subjected to 6-hour treatment with ciprofloxacin at 0.5 g/ml. Bacteria were
lysed to extract their genomic DNA. Equal amounts of DNA were spotted onto polyvinylidene difluoride (PVDF) membrane and probed with indicated antibodies.
Immunoblotting with antibodies for DNA served as a loading control. (B) Quantification of trapped GyrAHis. The intensity of anti–His-tag band from each sample in
(A) was corrected for the amount of input DNA, measured by the intensity of the
respective anti-DNA band. The adjusted GyrAHis signals were then normalized to
the signal of the WT strain, set as 1. Statistical significance was calculated using
two-tailed Mann-Whitney test in GraphPad Prism. *P < 0.05. **P < 0.01. A.U., arbitrary units. (C) Immunoblotting of purified E. coli (pgyrAHis) genomic DNA from
RADAR assays after ciprofloxacin treatment. E. coli genomic DNA samples were
either untreated, treated with benzonase or with ExoVII (1 U/l) at 37°C for 2 hours,
and then resolved by tris-glycine–SDS-PAGE and probed with anti–His-tag antibodies.
A representative blot of three independent experiments is shown.

ExoVII inhibitor synergizes with ciprofloxacin
While quinolones are widely used in the clinic, drug resistance
among pathogenic bacteria has become increasingly frequent (42).
While higher concentrations of quinolones might exert antimicrobial effects on the quinolone resistance strains, it is often limited by
adverse side effects in patients. Because our study (see Fig. 1) and
previous publications (11, 12, 14–16) show that genetic inactivation
of ExoVII leads to hypersensitization to quinolones, including in
the quinolone-resistant E. coli strains, we hypothesize that chemical
inhibitors of ExoVII could serve as “helper drugs” and enhance the
efficacy of quinolones in the resistant strains that are otherwise difficult to eradicate in patients.
To that end, we conducted a focused screen for ExoVII inhibitors
that could synergize with quinolones in the quinolone-resistant strain
(WT-pgyrA-S83L). We identified 7-(3-chlorophenyl)-1,3(2H,4H)-
isoquinolinedione (CPID) (Fig. 4A) from a family of isoquinolinedione compounds that was previously shown to inhibit human
TDP2 in vitro but did not synergize with etoposide (eukaryotic type
4 of 10
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IIA topoisomerase poison) in cultured cells (43). We found that
CPID was highly synergistic with ciprofloxacin in the quinolone-
resistant strain (WT-pgyrA-S83L) (Fig. 4B), while it was not synergistic
in the ExoVII-defcient strains (xseA-pgyrA-S83L or xseB-pgyrA-S83L),
suggesting that CPID acts as a specific inhibitor of ExoVII (Fig. 4C).
Consistent with this possibility, in vitro biochemical assays showed
that CPID inhibited ExoVII with an average IC50 (half-maximal
inhibitory concentration) of 2.4 M (Fig. 4D), while it failed to show
inhibitory activity against human TDP1 (43). CPID also showed
relatively low toxicity in two cell lines, human embryonic kidney
(HEK) 293 cells, and murine embryonic fibroblasts (MEFs) at concentrations up to 100 M after a 72-hour treatment (Fig. 4E). Combined, these results provide the proof of principle that successful
development of ExoVII inhibitors could help in mitigating the threat
of bacteria strains resistant to quinolones.
DISCUSSION

The DNA repair function of ExoVII uncovered here establishes
ExoVII as a prokaryotic functional analog of eukaryotic TDP2. It
A

is the first DNA-tyrosyl phosphodiesterase activity reported for
the bacterial domain, providing the missing link accounting for
the hypersensitivity of ExoVII-deficient strains to quinolones
(11, 12, 14–16, 21). ExoVII-mediated repair pathway, similar to
eukaryotic TDP-mediated pathways, likely evolved to resolve basal
levels of trapped type IIA TOPcc. Yet, topoisomerase poisons can
lead to markedly elevated levels of TOPcc such that the repair pathways become overwhelmed, which is why these therapeutics have
strong anticancer or antimicrobial effects. Nevertheless, the biological importance of ExoVII is underscored by its conservation
across the entire bacterial domain and in some archaea species as
well (44). A recent study also showed that, in response to quinolones,
the XseA subunit of ExoVII is activated by MarA, a transcription
factor associated with the multiple antibiotic resistance (mar) operon
in E. coli (15), further substantiating the significance of ExoVII in
antimicrobial resistance.
ExoVII is known to efficiently degrade single-stranded DNA,
including the single-stranded regions of DNA overhangs (13). Our
biochemical assays with ExoVII indicate that single-stranded overhang regions shorter than 4 nt are refractory to ExoVII cleavage,
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Fig. 4. CPID is a specific ExoVII inhibitor. (A) Chemical structure of 7-(3-chlorophenyl)-1,3(2H,4H)-isoquinolinedione (CPID). (B) CPID shows synergistic effect with ciprofloxacin in a quinolone-resistant strain, WT-pgyrA-S83L. (C) CPID does not synergize with ciprofloxacin in the quinolone-resistant strains deficient in either subunit of ExoVII.
(D) In vitro cleavage assay showing inhibition of ExoVII activity in a dose-dependent manner. Representative gel image and quantification are shown. IC50 value was
averaged from five independent experiments. (E) CPID is not toxic to HEK293 or MEF cells as determined by relative confluency of seeded cells after 72-hour treatment at
the indicated CPID concentration (n = 3; error bars represent SEM).
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while ExoVII exonuclease activity becomes increasingly processive
with longer single-stranded regions. We show that DNA substrates
with overhangs longer than 4 nt, including the tyrosine moiety
linked to a 4-nt overhang, are efficiently digested by ExoVII. The
activity of ExoVII appears to be fine-tuned so that it is primed for
DNA adducts at the end of 4-nt overhangs, which correspond to
trapped type IIA TOPcc in vivo (8, 25). We also found that ExoVII
can remove DNA gyrase from trapped TOPcc under conditions
where the polypeptide is denatured, similar to previous findings for
the eukaryotic TDP1 and TDP2 (36–41). These observations suggest that the substrate binding site of ExoVII is large enough to
accommodate the denatured type IIA topoisomerase polypeptide
covalently attached to single-stranded 5′-DNA ends.
Prokaryotic type IIA topoisomerases consist of DNA gyrase and
topoisomerase IV (Topo IV), where the two ubiquitous enzymes
have complementary yet partially overlapping biological functions
(42, 45). Here, we show that ExoVII directly excises DNA gyrase
TOPcc induced by quinolones, but quinolones actually trap both
DNA gyrase and Topo IV (42). In E. coli, a Gram-negative bacterium,
trapped DNA gyrase is the main source of quinolone-induced DNA
damage. The leading quinolone-resistant mutation on E. coli DNA
gyrase (gyrA-S83L) leads to decreased binding of quinolone to
DNA gyrase. Yet, in the gyrA-S83L strain, either a second mutation
on the DNA gyrase or a separate mutation on Topo IV can lead to
further quinolone resistance (42). Therefore, at higher quinolone concentrations, the mutated DNA gyrase (GyrA-S83L) is still trapped
by quinolones, and Topo IV TOPcc contributes to quinolone-induced
cell death. In addition, inactivation of ExoVII in Gram-positive bacteria also leads to hypersensitization to quinolones (21). Since Topo
IV is the primary target of quinolones in Gram-positive bacteria,
ExoVII likely plays a role in the repair of Topo IV TOPcc as well.
Current U.S. Food and Drug Administration (FDA) guidance
reserves the use of quinolones for the most serious bacterial infections due to their associated side effects and to limit the occurrence
of drug-resistant bacterial strains. Considering the role of ExoVII in
repairing quinolone-induced DNA damage, it is possible that lower
doses of quinolones combined with an ExoVII inhibitor could
achieve sufficient clinical benefits, thus decreasing the adverse side
effects of quinolones. Furthermore, in the case that bacterial strains
develop resistance to quinolones, ExoVII inhibitors may help to
partially restore the sensitivity to quinolones. The emergence of
multidrug- and pandrug-resistant bacterial strains poses a health
threat across the world. Yet, no new classes of antibiotics have been
approved by the FDA in nearly two decades. In this context, our
drug screen provides the proof of principle that ExoVII could be
targeted to boost the efficacy of quinolones and potentially overcome resistance to quinolones while limiting their side effects (46).
Because the substrates for ExoVII and TDP2 share significant
structural similarities (both repair enzymes resolve trapped type
IIA topoisomerases), it is plausible that some inhibitors can be
effective for both enzymes. One such example revealed here is CPID,
which belongs to a family of isoquinolinedione compounds. CPID
was previously reported to inhibit TDP2 in vitro (47), and here, we
demonstrate its inhibitory effect on ExoVII both in vitro and in vivo.
Notably, the strongest known TDP2 inhibitor (SV-5-153) failed to
inhibit ExoVII (our unpublished results), indicative of additional
undefined differences between ExoVII and TDP2. While further
studies on the class of isoquinolinedione compounds as ExoVII inhibitors are warranted, structural studies on the multimeric ExoVII
Huang et al., Sci. Adv. 2021; 7 : eabe0384
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will help elucidate any mechanistic difference with TDP2, a simpler
monomeric enzyme (48, 49).
MATERIALS AND METHODS

Generation of E. coli strains
Details of the E. coli strains used in this study are listed in Table 1.
All DNA primers used were obtained from Integrated DNA Technologies (IDT) with their sequences listed in Table 2. The parental
strains (WT, xseA, and xseB) were obtained from Coli Genetic
Stock Center at the Yale University. The complete gyrA gene including its endogenous promoter and a C-terminal His-tag was cloned
from the genomic DNA of E. coli K-12 MG1655 strain using gyrAHis
forward primer (FP) and backward primer (BP) and introduced into
single-copy plasmid pBeloBac11 [New England Biolabs (NEB)] at
Bam HI and Hind III sites using In-Fusion (TaKaRa). The plasmids
bearing gyrAHis (pgyrAHis) were used to transform into the three
parental strains using Transformation & Storage Solution (TSS)
transformation protocol and selected on Lysogeny Broth (LB, 10 g
salt)-chloramphenicol (Cm) (10 g/ml). Transformants were verified with immunoblotting. To generate quinolone-resistant strains,
mutation gyrA-S83L was introduced into the same plasmid using
QuikChange Lightning (Agilent) and gyrA-S83L FP and BP before
establishing transformants. To delete the genomic copy of gyrA, we
first transformed a derivative of WT E. coli MG1655 carrying the
lambda Red recombineering functions with pgyrAHis, selected on
LB-Cm (10 g/ml) and purified once on the same media at 32°C. A
transformant was grown in 10 ml of LB-Cm (10 g/ml) at 32°C to
an OD600 (optical density at 600 nm) of 0.6, and Red function expression was induced for 15 min at 42°C. Cells were centrifuged
and washed four times in ice-cold sterile water and electroporated
with 100 ng of a zeoR cassette containing 40–base pair (bp) homologies upstream and downstream of gyrA generated by polymerase
chain reaction (PCR) with gyrA-KO-zeo-FP and BP. After a 1-hour
recovery in 1 ml of LB, chromosomal gyrA knockout clones were
selected on LB plates in the presence of Cm (10 g/ml) and Zeo
(25 g/ml) and incubated at 37°C overnight. Colonies were purified
thrice more, and the disruption of genomic gyrA was verified by PCR
using primers gyrA-KO-FP and BP. A P1 lysate was generated from
the knockout cells, and P1 transduction was carried out on cells carrying pBeloBac-gyrA-S83Lhis, as described previously (50). The disruption of the genomic gyrA in these strains was verified by PCR
using primers gyrA-KO-FP and BP. pYtopA and pYtopA-R327W
were generated using pBAD/TOPO ThioFusion Expression Kit
(Thermo Fisher Scientific), as previously described (24), and transformants of all three plasmids in the parental strains were obtained
using TSS transformation protocol and selected with Ampicillin
(100 g/ml).
Spotting and cell killing assays
Exponentially growing E. coli cultures were diluted to OD600 of
10−6, then 5 l of fivefold serial dilution was spotted onto LB plates
containing indicated concentration of ciprofloxacin or nalidixic
acid, and incubated at 37°C overnight. For determination of MIC of
ciprofloxacin, 200 l of exponentially growing culture (OD600 = 10−1)
was plated on LB plates, then the MIC ciprofloxacin test strips
(Liofilchem) were applied to the plates, and incubated at 37°C overnight following the manufacturer’s instruction. Cell-killing assays
were carried out as previously described (22). Briefly, transformants
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Table 1. List of strains.
AQ24

Name

Genotype

Source

WT

BW25113

Yale Coli Genetic Stock Center

xseA

BW25113 xseA::Kn. KanR

Yale Coli Genetic Stock Center

xseB

R

BW25113 xseB::Kn. Kan

Yale Coli Genetic Stock Center

NM1100

MG1655 mini ::tet, recombineering strain

Current study

NM50000

NM1100 pBeloBac-gyrAhis recombineered with gyrA::zeo.
CmR ZeoR TetS

Current study

WT-pgyrA-S83L

BW25113 pBeloBac-gyrA-S83Lhis transduced with gyrA::zeo
from NM50000. CmR ZeoR

Current study

xseA-pgyrA-S83L

BW25113 xseA::Kn pBeloBac-gyrA-S83Lhis transduced with
gyrA::zeo from NM50000. CmR ZeoR

Current study

xseB-pgyrA-S83L

BW25113 xseB::Kn pBeloBac-gyrA-S83Lhis transduced with
gyrA::zeo from NM50000. CmR ZeoR

Current study

BW25113 pBAD/Thio. AmpR

Current study

WT-pBAD/Thio
xseA-pBAD/Thio

BW25113 xseA::Kn pBAD/Thio. AmpR

Current study

xseB-pBAD/Thio

R

Current study

BW25113 xseB::Kn pBAD/Thio. Amp
BW25113 pBAD/Thio-YtopA. AmpR

WT-pYtopA

Current study
R

Current study

R

Current study

BW25113 xseA::Kn pBAD/Thio-YtopA. Amp

xseA-pYtopA

BW25113 xseB::Kn pBAD/Thio-YtopA. Amp

xseB-pYtopA

R

WT-pYtopA-R327W

BW25113 pBAD/Thio-YtopA-R327W. Amp

Current study

xseA-pYtopA-R327W

BW25113 xseA::Kn pBAD/Thio-YtopA-R327W. Amp

R

Current study

xseB-pYtopA-R327W

BW25113 xseB::Kn pBAD/Thio-YtopA-R327W. AmpR

Current study

R

WT-pgyrAHis

BW25113 pBeloBac-gyrAhis. Cm

xseA-pgyrAHis

Current study

BW25113 xseA::Kn pBeloBac-gyrAhis. CmR

Current study

R

Current study

BW25113 xseB::Kn pBeloBac-gyrAhis. Cm

xseB-pgyrAHis

Table 2. List of primers.
Name

Sequence

gyrAHis FP

5′-CGGTACCCGGGGATCCGGATGTGAATAAAGCGTATAGG

gyrAHis BP

5′-TAGAATACTCAAGCTTTTAGTGGTGATGGTGATGATGTTCTTCTTCTGGCTCGTCGTCAACG

gyrA-S83L FP

5′-CATGGTGACTTGGCGGTCTAT

gyrA-S83L BP

5′-ATAGACCGCCAAGTCACCATG

gyrA-KO-zeo-FP

5′-TACTCCGTAATTGGCAAGACAAACGAGTATATCAGGCATTGTTGACAATTAATCATCGGC

gyrA-KO-zeo-BP

5′-AAGGGAGATAGCTCCCTTTTGGCATGAAGAAGTAAAATTATCAGTCCTGCTCCTCGGCCA

gyrA-KO-FP

5′-TCATTGGCACTTCTACTCCG

gyrA-KO-BP

5′-AAGGGAGATAGCTCCCTTTT

harboring pBAD/Thio, pYtopA or pYtopA-R327W, were grown in
LB with 2% glucose and carbenicillin (50 g/ml) overnight and diluted 1:100 in LB with carbenicillin (50 g/ml) and grown to OD600
of 0.4. YTop1 or YTop1-R327W was induced by the addition of
0.2% arabinose for 0.5 to 2 hours. Postinduction cultures were
then serially diluted and spotted onto LB plates with 2% glucose
and carbenicillin (50 g/ml) and incubated at 37°C overnight.
Alternatively, exponentially growing transformants were serially
Huang et al., Sci. Adv. 2021; 7 : eabe0384
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diluted as indicated and spotted on LB plates containing carbenicillin
(50 g/ml) and indicated concentrations of arabinose and incubated
at 37°C overnight.
Screen for ExoVII inhibitor
Exponentially growing WT-pgyrA-S83L, xseA-pgyrA-S83L, or
xseA-pgyrA-S83L at OD600 of 3 × 10−4 was combined with equal
volume of media containing indicated inhibitor concentrations
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with or without ciprofloxacin at indicated concentrations in clear-
bottom 96-well plates. OD600 was measured at the end of 4-hour
incubation at 37°C shaking at 225 rpm, and cell densities were normalized to samples without any drug treatment. Toxicity of compounds
was measured by treating either HEK293 or MEF cells (1000 cells in
96-well plates seeded 24 hours prior) with indicated concentrations
of ExoVII inhibitor for 72 hours. The samples were imaged with a
Cytation 5 (BioTek), and the confluency of each well was normalized to untreated samples.
Generation of DNA constructs and biochemical assays
The biochemical constructs for ExoVII activity were generated as
described previously (31). All oligonucleotides were synthesized by
IDT or Midland, and all sequences of DNA oligos are listed in
Table 3. For the series of constructs with different chemical groups
on 5′-overhangs, a 22-nt DNA with three phosphorothioate bonds
on the 3′-ends (T-22-3PT) was labeled with 32P at the 5′-end with
[-32P]ATP (adenosine triphosphate) (PerkinElmer Life Sciences)
and T4 polynucleotide kinase (NEB) and then purified by mini

Quick Spin Oligo Columns (Sigma-Aldrich). An 18-nt DNA harboring different chemical groups at the 5′-end (P-18, OH-18, or
Y-18) was mixed with the 5′-labeled T-22-3PT before annealing to
a complementary strand between 34 and 40 nt long (B-34, B-36,
B-38, and B-40) at 1:1:1 ratio. The nicks were sealed with T4 DNA
ligase (NEB). For constructs longer than 40 bp, an additional middle
piece (M-20 or M-40) was also included in the annealing reaction,
with the appropriate complementary strands (B-56 or B-76) before
ligation to generate Y-60 and Y-80, each with 4-nt 5′-overhangs.
To generate Y-19 with 4-nt 5′-overhangs, Y-18 was labeled on the
3′-end with [-32P] cordycepin and terminal transferase (NEB), then
purified by mini Quick Spin Oligo Columns (Sigma-Aldrich), and
annealed to B-15 at 1:1 ratio. To generate RNA constructs with
5′-phosphotyrosine, T-22-3PT was labeled with 32P at the 5′-end as
described before, mixed with Y-10-DNA or Y-10-RNA, before annealing to B-28 or B-32 at 1:1:1 ratio in the presence of RNasin Plus
(3 U/l; Promega). For the series of constructs with different chemical groups on 3′-overhangs, a 14-nt DNA harboring different
chemical groups at the 3′-end (14-P, 14-OH, or 14-Y) was labeled

Table 3. List of DNA oligos.
Name

Sequence

Modification

T-22-3PT

5’-GCGCAGCTAGCGGCGGATG*G*C*A

* = phosphorothioate bond

P-18

5’-P-TCCGTTGAAGCCTGCTTT

P = phosphate

OH-18

5’-TCCGTTGAAGCCTGCTTT

Y-18

5’-Y-TCCGTTGAAGCCTGCTTT

OH-19

5’-TTCCGTTGAAGCCTGCTTT

B-34

5’-TGCCATCCGCCGCTAGCTGCGCAAAGCAGGCTTC

B-36

5’-TGCCATCCGCCGCTAGCTGCGCAAAGCAGGCTTCAA

B-38

5’-TGCCATCCGCCGCTAGCTGCGCAAAGCAGGCTTCAACG

B-40

5’-TGCCATCCGCCGCTAGCTGCGCAAAGCAGGCTTCAACGGA

B-15

5’-TAAAGCAGGCTTCAA

B-56

5’-TGCCATCCGCCGCTAGCTGCGCA
CTCTTGACCCTACGACGATAAAGCAGGCTTCAA

B-76

5’-TGCCATCCGCCGCTAGCTGCGCACTCTTGACCCTAC
GACGATACTCTTGACCCTACGACGATAAAGCAGGCTTCAA

M-20

5’-P-ATCGTCGTAGGGTCAAGAGT

P = phosphate

M-40

5’-P-ATCGTCGTAGGGTCAAGAGTATCGTCGTAGGGTCAAGAGT

P = phosphate

Y-10-DNA

5’-Y-TTAAAACAGC

Y = phosphotyrosine

Y-10-RNA

5’Y-rUrUrArArArArCrArGrC

Y = phosphotyrosine

B-28

5’-TGCCATCCGCCGCTAGCTGCGCGCTGTT

B-32

5’-TGCCATCCGCCGCTAGCTGCGCGCTGTTTTAA

T-22

5’-GCGCAGCTAGCGGCGGATGGCA

14-P

5’-GATCTAAAAGACTT-P

14-OH

5’-GATCTAAAAGACTT

14-Y

5’-GATCTAAAAGACTT-Y

B-32-3Y

5’-CTTTTAGATCTGCCATCCGCCGCTAGCTGCGC

B-36-3Y

5’-AAGTCTTTTAGATCTGCCATCCGCCGCTAGCTGCGC

T-22-15PT

5’-GCGCAGC*T*A*G*C*G*G*C*G*G*A*T*G*G*C*A

Gyr-1

5’-GAATCATAATGGGGAAGGCCATCCAGCCTC

Gyr-2

5’-TGAGGCTGGATGGCCTTCCCCATTATGATTC

Huang et al., Sci. Adv. 2021; 7 : eabe0384
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Y = phosphotyrosine

P = phosphate
Y = phosphotyrosine

* = phosphorothioate bond
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with 32P at the 5′-end as described before, then mixed with T-22, and
annealed to B-32-3Y or B-36-3Y at 1:1:1 ratio, followed by DNA ligation. For single-stranded constructs, T-22-15PT (15 phosphorothioate bonds on the 3′-ends) was labeled with 32P at the 5′-end as
described before, then mixed with OH-18 or Y-18 at 1:1 ratio, and
ligated with T4 RNA Ligase 1 (NEB) following the manufacturer’s
instructions. For generation of E. coli DNA gyrase cleavage complexes, Gyr-1 was labeled on the 3′-end with [-32P] cordycepin
and terminal transferase (NEB), then purified by mini Quick Spin
Oligo Columns (Sigma-Aldrich), and annealed to Gyr-2 at 1:1 ratio.
Reactions with ExoVII (Thermo Fisher Scientific or NEB) were
performed in 10 l of reaction containing 20 to 100 nM internally
radiolabeled DNA substrate and indicated concentration of ExoVII
in buffer with 50 mM potassium acetate, 20 mM tris-acetate (pH 7.9),
10 mM magnesium acetate, and 1 mM dithiothreitol (DTT). ExoVII
reactions were incubated at 37°C for 1 or 2 hours followed by inactivation at 55°C for 30 min before being terminated by the addition
of 20 l of formamide gel loading buffer [96% (v/v) formamide,
10 mM ethylenediaminetetraacetic acid, 1% (w/v) xylene cyanol,
and 1% (w/v) bromophenol blue]. For IC50 determination, ExoVII
was preincubated with the inhibitor at 25°C for 5 min before the
addition of equal volume of DNA solution, and the reaction continued
for another 20 to 30 min. The 10 l of reaction contained ExoVII
(0.025 U/l), 20 to 100 nM internally radiolabeled DNA substrate,
and indicated inhibitor concentration in buffer with 50 mM potassium acetate, 20 mM tris-acetate (pH 7.9), 10 mM magnesium acetate, 1 mM DTT, and 10% (v/v) dimethyl sulfoxide. The percentage
of products in the presence of inhibitor was normalized to that of
control reaction without any inhibitors, and the resulting plot was
fitted to a nonlinear regression function in Prism. DNA gyrase was
purified as previously described (51). Reactions with DNA gyrase
were performed in 10 l of reaction containing 20 to 100 nM radiolabeled DNA substrate, 40 nM DNA gyrase, and 250 nM ciprofloxacin when indicated. Reaction buffer contains 35 mM tris-HCl
(pH 7.5), 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.7 mM spermidine, bovine serum albumin (0.36 mg/ml), 1 mM ATP, and 6.5%
glycerol. After incubation at 25°C for 1 hour, ExoVII (0.375 to
1.5 U/l) was added, and the reactions were incubated further at
37°C for 3 hours. The reactions were stopped with 0.2% SDS and
20 l of formamide gel loading buffer [96% (v/v) formamide, 10 mM
ethylenediaminetetraacetic acid, 1% (w/v) xylene cyanol, and 1% (w/v)
bromophenol blue]. All samples were heat denatured at 95°C for
5 min and analyzed by denaturing polyacrylamide gel electrophoresis
(PAGE) (20%). Gels were dried and exposed on PhosphorImager
screens. Imaging was done using a Typhoon 8600 imager (GE
Healthcare, Little Chalfont, United Kingdom).
RADAR assays
Exponentially growing E. coli cells (OD600 = 0.4) were treated with
ciprofloxacin (0.5 g/ml) for 6 hours, and then 1 ml of treated cells
was directly combined with 4 ml of 1.25× lysis buffer [7.5 M guanidinium isothiocyanate, 12.5 mM tris-HCl (pH 6.5), 25 mM EDTA,
5% Triton X-100, and 1.25% lauroylsarcosine]. The lysates were
sonicated for three cycles, each for 15 s at 60% power, and then were
phenol-chloroform extracted twice. The samples were ethanol precipitated, and the DNA pellets washed twice with 80% ethanol
before being air-dried. The DNA pellets were resuspended in 8 mM
NaOH, and DNA concentrations of samples were quantified. Equal
amount of DNA (8 g) of each sample was blotted on polyvinylidene
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difluoride (PVDF) membrane and probed with anti–His-tag rabbit
monoclonal antibody (Cell Signaling) and anti–double-stranded
DNA mouse monoclonal antibody (Abcam), and the band intensities were quantified by ChemiDoc System (Bio-Rad). Alternatively,
5 g of purified DNA from ciprofloxacin-treated samples was treated
with benzonase (25 U/l; Millipore Sigma) or ExoVII (1 U/l) at
37°C for 2 hours in a buffer containing 50 mM potassium acetate,
20 mM tris-acetate (pH 7.9), 10 mM magnesium acetate, and 1 mM
DTT. The samples were then resolved on a 6% tris-glycine gel, and
immunoblotting was done following standard procedures and probed
with anti–His-tag rabbit monoclonal antibody (Cell Signaling).
SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/10/eabe0384/DC1
View/request a protocol for this paper from Bio-protocol.
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